May 03, 2022
2 min watch
Save
VIDEO: Dry eye treatment improves signs, symptoms at 1 week
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
DENVER — A large phase 2b study showed that the use of Aerie Pharmaceuticals’ AR-15512 compound resulted in improved tear production and dry eye symptoms at 7 days and 14 days, according to David Wirta, MD, of the Eye Research Foundation.
The TRPM8 cold thermoreceptor agonist affects the receptors on the conjunctiva, cornea and eyelid to stimulate a cold feeling to the eye, leading to reflex tearing, Wirta said.
Published by:
Sources/Disclosures
Collapse
Source:
Wirta D, et al. Dry eye sign, symptom and quality of life improvements associated with administration of AR-15512. Presented at: Association for Research in Vision and Ophthalmology meeting; May 1-4, 2022; Denver.
Disclosures:
Wirta reports receiving grant support from Aerie Pharmaceuticals as principal investigator for this study.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.